Canada markets closed
  • S&P/TSX

    20,287.80
    -23.98 (-0.12%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • DOW

    34,935.47
    -149.06 (-0.42%)
     
  • CAD/USD

    0.8024
    -0.0015 (-0.18%)
     
  • CRUDE OIL

    73.81
    +0.19 (+0.26%)
     
  • BTC-CAD

    52,035.92
    -83.33 (-0.16%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • GOLD FUTURES

    1,812.50
    -18.70 (-1.02%)
     
  • RUSSELL 2000

    2,226.25
    -13.78 (-0.62%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • NASDAQ

    14,672.68
    -105.59 (-0.71%)
     
  • VOLATILITY

    18.24
    +0.54 (+3.05%)
     
  • FTSE

    7,032.30
    -46.12 (-0.65%)
     
  • NIKKEI 225

    27,283.59
    -498.83 (-1.80%)
     
  • CAD/EUR

    0.6756
    -0.0002 (-0.03%)
     

Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued

·4 min read

- By GF Value

The stock of Inovio Pharmaceuticals (NAS:INO, 30-year Financials) is believed to be significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $9.15 per share and the market cap of $1.9 billion, Inovio Pharmaceuticals stock appears to be significantly overvalued. GF Value for Inovio Pharmaceuticals is shown in the chart below.


Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued
Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued

Because Inovio Pharmaceuticals is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which is estimated to grow 165.26% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Inovio Pharmaceuticals has a cash-to-debt ratio of 15.30, which ranks in the middle range of the companies in Biotechnology industry. Based on this, GuruFocus ranks Inovio Pharmaceuticals's financial strength as 5 out of 10, suggesting fair balance sheet. This is the debt and cash of Inovio Pharmaceuticals over the past years:

Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued
Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued

It poses less risk to invest in profitable companies, especially those that have demonstrated consistent profitability over the long term. A company with high profit margins is also typically a safer investment than one with low profit margins. Inovio Pharmaceuticals has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $6.5 million and loss of $1.1 a share. Its operating margin is -2345.52%, which ranks worse than 81% of the companies in Biotechnology industry. Overall, GuruFocus ranks the profitability of Inovio Pharmaceuticals at 1 out of 10, which indicates poor profitability. This is the revenue and net income of Inovio Pharmaceuticals over the past years:

Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued
Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Inovio Pharmaceuticals is -54.7%, which ranks worse than 84% of the companies in Biotechnology industry. The 3-year average EBITDA growth rate is 2.3%, which ranks in the middle range of the companies in Biotechnology industry.

Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Inovio Pharmaceuticals's return on invested capital is -173.12, and its cost of capital is 4.93.

In closing, The stock of Inovio Pharmaceuticals (NAS:INO, 30-year Financials) gives every indication of being significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks in the middle range of the companies in Biotechnology industry. To learn more about Inovio Pharmaceuticals stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting